These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24121170)

  • 1. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
    Farrell JM; Pang JC; Kim GE; Tabatabai ZL
    Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.
    Tang LH; Gonen M; Hedvat C; Modlin IM; Klimstra DS
    Am J Surg Pathol; 2012 Dec; 36(12):1761-70. PubMed ID: 23026928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center.
    Han X; Xu X; Jin D; Wang D; Ji Y; Lou W
    Pancreas; 2014 May; 43(4):526-31. PubMed ID: 24658317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors.
    Sun Y; Lohse C; Smyrk T; Hobday T; Kroneman T; Zhang L
    Am J Surg Pathol; 2018 Feb; 42(2):247-255. PubMed ID: 29016403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors.
    Philips P; Kooby DA; Maithel S; Merchant NB; Weber SM; Winslow ER; Ahmad S; Kim HJ; Scoggins CR; McMasters KM; Martin RCG
    Pancreas; 2018 Mar; 47(3):326-331. PubMed ID: 29351120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.
    Lee HE; Mounajjed T; Erickson LA; Wu TT
    Endocr Pathol; 2016 Sep; 27(3):259-67. PubMed ID: 27306997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grading by the Ki-67 Labeling Index of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy Specimens of Pancreatic Neuroendocrine Tumors Can Be Underestimated.
    Hwang HS; Kim Y; An S; Kim SJ; Kim JY; Kim SY; Hwang DW; Park DH; Lee SS; Kim SC; Seo DW; Hong SM
    Pancreas; 2018; 47(10):1296-1303. PubMed ID: 30211805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
    Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms.
    Simtniece Z; Vanags A; Strumfa I; Sperga M; Vasko E; Prieditis P; Trapencieris P; Gardovskis J
    Pol J Pathol; 2015 Jun; 66(2):176-94. PubMed ID: 26247532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.
    Aysal A; Agalar C; Egeli T; Unek T; Oztop I; Obuz F; Sagol O
    Endocr Pathol; 2021 Dec; 32(4):461-472. PubMed ID: 34283399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subgrading of G2 Pancreatic Neuroendocrine Tumors as 2A (Ki67 3% to < 10%) Versus 2B (10% to ≤ 20%) Identifies Behaviorally Distinct Subsets in Keeping with the Evolving Management Protocols.
    Eren OC; Bagci P; Balci S; Ohike N; Saka B; Sokmensuer C; Leblebici CB; Xue Y; Reid MD; Krasinskas AM; Kooby D; Maithel SK; Sarmiento J; Cheng JD; Taskin OC; Kapran Y; Tarcan ZC; Luchini C; Scarpa A; Basturk O; Adsay NV
    Ann Surg Oncol; 2024 Oct; 31(10):7001-7011. PubMed ID: 38955993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.